ArticleClinical and experimental nephrology2026
The prevalence of IgA nephropathy in Japan: results from a nationwide survey.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPrecise epidemiological statistics regarding IgA nephropathy (IgAN) are essential for healthcare resource allocation and optimal therapeutic management. However, a nationwide epidemiological study has not been conducted in Japan over the past twenty years.
methodsWe conducted a mail-based survey targeting departments at hospitals to estimate the annual numbers of patients with IgAN in 2022. Departments were selected using stratified random sampling based on specialty and hospital size, and a total of 2148 departments (nephrology, pediatrics, and urology) were included in the analysis. The overall and sex-specific annual numbers of patients with IgAN were estimated, along with the number of patients with high disease activity. The corresponding prevalence was calculated using these estimates, divided by the midyear population of Japan in 2022.
resultsA total of 702 departments responded to the survey representing an overall response rate of 32.7%. The estimated numbers of patients with IgAN were 103,800 (95% confidence interval [CI] 83,431-124,170), including 50,160 men (95% CI 40,034-60,287) and 53,640 women (95% CI 42,799-64,481). The annual prevalence of IgAN was 83.1 per 100,000 population (men: 82.6 women: 83.6), with a male-to-female ratio of 0.99. The estimated numbers of IgAN patients with high disease activity were 15,646 (95% CI 12,464-18,828).
conclusionsThis nationwide survey provides updated estimates of the prevalence of IgAN and the number of the IgAN patients with high disease activity in Japan. The prevalence of IgAN has risen substantially over the past twenty years.
Indexed as
Identifiers
42801414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.